Journal: Scientific Reports

Article Title: The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells

doi: 10.1038/s41598-021-96521-2

Figure Lengend Snippet: Involvement of DNA damage signaling in the induction of mRNA expression of CXCL9/10/11 by T-DXd in HER2-positive GC cells. ( A ) Comparison of mRNA expression (z-score) of CXCL9 , CXCL10 , and CXCL11 between ERBB2 amplified GC tissues (Amp) (n = 55) and ERBB2 non-amplified GC tissues (Diploid) (n = 238) from TCGA dataset. ( B ) Correlation among mRNA expression (z-score) of CXCL9 , CXCL10 , CXCL11 , CHEK1 , CHEK2 , and TP53 in samples from 412 patients with GC from TCGA dataset. ( C ) qPCR analysis of CXCL9, CXCL10, and CXCL11 in NCI-N87 cells treated with 1 μg/ml T-DXd in the absence or presence of 10 μM KU-55933 (KU), 10 μM VE-821 (VE), or 100 nM UCN-01 (UCN) for 72 h (n = 3). Values are shown as means ± SEM. * P < 0.05, ** P < 0.01, **** P < 0.0001.

Article Snippet: Other reagents used in this study were acquired from the indicated suppliers: trastuzumab (Chugai Pharmaceutical Corporation, Tokyo, Japan); KU-55933, VE-821, and UCN-01 (Merck Sigma-Aldrich, St. Louis, MO, USA); IFN-γ (R&D systems, Minneapolis, MN, USA); irinotecan (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan); ultra-LEAF purified human IgG1 isotype control recombinant antibody (BioLegend, San Diego, CA, USA); FITC mouse anti-human HER-2/neu (340553), FITC mouse IgG1 κ isotype control (555909), and 7-AAD (559925) (BD Biosciences, San Jose, CA, USA); PE anti-human HLA-ABC monoclonal antibody (W6/32) (12-9983-42), Alexa Fluor 488 anti-human CD326 (EpCAM) (53-8326-41), and PE mouse IgG2a κ isotype control (eBM2a) (12-4724-81) (Thermo Fisher Scientific, Waltham, MA, USA); HER2/ErbB2 rabbit mAb (#4290), Phospho-Akt rabbit mAb(#4060), Akt (pan) rabbit mAb (#4691), Phospho-ERK1/2 rabbit mAb (#4370), and ERK1/2 rabbit mAb (#4695) (Cell Signaling Technology, Danvers, MA, USA); anti-human HLA class I (HLA-ABC) mAb (D367-3) (Medical & Biological Laboratory, Aichi, Japan); Anti-β-actin antibody (sc-69879) (Santa Cruz Biotechnology, Dallas, TX, USA).

Techniques: Expressing, Amplification

Journal: Scientific Reports

Article Title: TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition

doi: 10.1038/s41598-018-31682-1

Figure Lengend Snippet: Antibodies and evaluation methods used in this study.

Article Snippet: HER-2 , mouse anti-human* , CB11 , Novocastra , , .

Techniques:

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

doi: 10.1186/s13046-017-0653-7

Figure Lengend Snippet: Osimertinib induces cell surface expression of HER-2. a PC9 and PC9-T790M cells were treated with the indicated concentrations of osimertinib for 24 h, then cell lysates were immunoblotted to detect the indicated proteins. The immunoreactive spots were quantified by densitometric analysis, ratios of EGFR/Actin and HER2/Actin were calculated and values, expressed as fold increase versus control (control value = 1), are reported. Results are representative of two independent experiments. PC9 and PC9-T790M cell lines were treated with the indicated concentrations of osimertinib for 24 h ( b ) or with 30 nM osimertinib for 24 and 48 h ( c ), then HER-2 protein levels on cell surface was evaluated by flow-cytometry, quantified as MEF, and expressed as fold increase versus control (control value = 1). Mean values of three independent measurements (±SD) are shown (** p < 0.01, *** p < 0.001 versus control; one-way analysis of variance followed by Bonferroni’s post-test)

Article Snippet: One million of NSCLC cells were incubated, for one hour at room temperature, with Isotype control Monoclonal Mouse IgG1/R-PE (Ancell IRP, Bayport, MN), mouse anti-Human HER-2/PE or mouse anti-Human EGFR/PE (BD Biosciences, San Josè CA) to determine EGFR or HER-2 protein membrane levels as previously described [ ].

Techniques: Expressing, Flow Cytometry